JOPIC

The JoPIC is an independent-unbiased, peer-reviewed, and open-access journal of current national and international issues and reviews for original clinical and experimental research, interesting case reports, surgical techniques, differential diagnoses, editorial opinions, letters to the editor, and educational papers in pulmonology, thoracic surgery, occupational diseases, allergology, and intensive care medicine.

EndNote Style
Index
Review
Behçet’s disease and pulmonary involvement
Behçet’s disease (BD) is a systemic vasculitis involving arteries and veins of all sizes and is characterized by a heterogeneous spectrum of clinical manifestations, including mucocutaneous, ocular, vascular, and neurological involvement, typically following a relapsing-remitting course. Although thoracic involvement is infrequent, it can affect various anatomical structures within the chest and present with a wide range of clinical symptoms. Pulmonary artery involvement may lead to life-threatening complications such as pulmonary artery aneurysms (PAAs) and pulmonary artery thrombosis (PAT), which are significant causes of mortality in BD. Timeyl diagnosis, appropriate radiological assessment, prompt initiation of immunosuppressive therapy are critical to reducing morbidity and mortality. This review provides an overview of the pulmonary manifestations of BD.


1. Feigenbaum A. Description of Behçet’s syndrome in the Hippocratic third book of endemic diseases.Br J Ophthalmol. 1956;40(6):355-357. doi:10.1136/bjo.40.6.355
2. Adil A, Goyal A, Quint JM. Behcet disease. In:StatPearls. Treasure Island (FL): StatPearls Publishing; February 22, 2023.
3. de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies.Arthritis Rheum. 2009;61(10):1287-1296. doi:10.1002/art.24642
4. Muñoz SA, Kostianovsky A, Allievi A, Orden AO. Behçet disease in Latin American countries: a systematic literature review of demographic and clinical features, and HLA-B*51 allele frequency.Reumatol Clin (Engl Ed). 2023;19(7):386-391. doi:10.1016/j.reumae.2022.12.005
5. Hatemi G, Seyahi E, Fresko I, Talarico R, Uçar D, Hamuryudan V. Behçet’s syndrome: one year in review 2024.Clin Exp Rheumatol. 2024; 42(10):1999-2007. doi:10.55563/clinexprheumatol/fqao16
6. Kiafar M, Faezi ST, Kasaeian A, et al. Diagnosis of Behçet’s disease: clinical characteristics, diagnostic criteria, and differential diagnoses.BMC Rheumatol. 2021;5(1):2. doi:10.1186/s41927-020-00172-1
7. International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria.J Eur Acad Dermatol Venereol. 2014; 28(3):338-347. doi:10.1111/jdv.12107
8. Kırkıl G. Behçet hastalığı ve akciğerler. Karalezli A, editör. Romatolojik hastalıklar ve akciğerler. 1. Baskı. Ankara: Türkiye Klinikleri; 2021.
9. Bilgin G, Sungur G, Kucukterzi V. Systemic and pulmonary screening of patients with Behçet’s disease during periodic follow-up.Respir Med. 2013;107(3):466-471. doi:10.1016/j.rmed.2012.04.005
10. Ceylan N, Bayraktaroglu S, Erturk SM, Savas R, Alper H. Pulmonary and vascular manifestations of Behcet disease: imaging findings.AJR Am J Roentgenol. 2010;194(2):W158-W164. doi:10.2214/AJR.09.2763
11. Kılıç H, Çınar Hancıoğlu Z. Vaskülitik sendromlar ve akciğerler. In: Karalezli A, ed. Romatolojik hastalıklar ve akciğerler. 1st ed. Ankara: Türkiye Klinikleri; 2021.
12. Hatemi G, Uçar D, Uygunoğlu U, Yazici H, Yazici Y. Behçet syndrome.Rheum Dis Clin North Am. 2023;49(3):585-602. doi:10.1016/j.rdc.2023. 03.010
13. Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients.Medicine (Baltimore). 2012;91(1):35-48. doi:10.1097/MD. 0b013e318242ff37
14. Desbois AC, Wechsler B, Cluzel P, et al. Atteintes cardiovasculaires de la maladie de Behçet [Cardiovascular involvement in Behçet’s disease].Rev Med Interne. 2014;35(2):103-111. doi:10.1016/j.revmed.2013.12.002
15. Ghembaza A, Boussouar S, Saadoun D. Atteintes thoraciques de la maladie de Behçet [Thoracic manifestations of Behcet’s disease].Rev Mal Respir. 2022;39(6):523-533. doi:10.1016/j.rmr.2022.04.010
16. Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Behçet syndrome.Am J Med. 2004;117(11):867-870. doi:10.1016/j.amjmed.2004.05.027
17. Hamuryudan V, Yurdakul S, Moral F, et al. Pulmonary arterial aneurysms in Behçet’s syndrome: a report of 24 cases.Br J Rheumatol. 1994;33(1):48-51. doi:10.1093/rheumatology/33.1.48
18. Erkan F, Kiyan E, Tunaci A. Pulmonary complications of Behçet’s disease. Clin Chest Med. 2002;23(2):493-503. doi:10.1016/s0272-5231(01) 00014-4
19. Tezcan ME, Isci B. Pulmonary multiple cystic lesions in a patient with Behçet’s syndrome. Reumatismo. 2019;71(2):103-104. doi:10.4081/reumatismo.2019.1124
20. Kone-Paut I, Barete S, Bodaghi B, et al. French recommendations for the management of Behçet’s disease.Orphanet J Rare Dis. 2021;16(Suppl 1):352. doi:10.1186/s13023-020-01620-4
21. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome.Ann Rheum Dis. 2018;77(6):808-818. doi:10.1136/annrheumdis-2018-213225
22. Karadag O, Bolek EC. Management of Behcet’s syndrome. Rheumatology (Oxford). 2020;59(Suppl 3):iii108-iii117. doi:10.1093/rheumatology/keaa086
23. Moriano Morales C, Graña Gil J, Brito García N, et al. SER recommendations on treatment of refractory Behçet’s syndrome.Reumatol Clin (Engl Ed). 2024;20(4):204-217. doi:10.1016/j.reumae.2023. 12.006
Volume 3, Issue 3, 2025
Page : 83-85
_Footer